Sputum microbiota in people with cystic fibrosis starting on Elexacaftor/Tezacaftor/Ivacaftor
The goal of this study was to determine the effects of Elexacaftor/Tezacaftor/Ivacaftor on bacteria in sputum of people with cystic fibrosis. Induced or spontaneously expectorated sputum was collected before, and 1, 3, and 6 months after initiating Elexacaftor/Tezacaftor/Ivacaftor treatment. 16S rRNA gene sequencing was used to comprehensively measure sputum bacteria.